Meeting
2019 ASCO Annual Meeting
Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS).
Authors
Sonja Zweegman
Department of Hematology, Amsterdam UMC, Amsterdam, Netherlands
Sonja Zweegman , Saad Zafar Usmani , Katherine Chastain , Jodi Carey , Karen Ren , Elena Smith , Maria Krevvata , Jianping Wang , Jessica Vermeulen , Thierry Facon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03652064
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS8056)
DOI
10.1200/JCO.2019.37.15_suppl.TPS8056
Abstract #
TPS8056
Poster Bd #
380a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).
First Author: Pieter Sonneveld
Poster
2021 ASCO Annual Meeting
ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended for early autologous transplantation.
First Author: Shaji Kumar
Poster
2020 ASCO Virtual Scientific Program
DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM).
First Author: Saad Zafar Usmani
Poster
2018 ASCO Annual Meeting
Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).
First Author: Pieter Sonneveld